148 related articles for article (PubMed ID: 22403733)
1. A highly sensitive quantitative real-time PCR assay for determination of mutant JAK2 exon 12 allele burden.
Kjær L; Westman M; Hasselbalch Riley C; Høgdall E; Weis Bjerrum O; Hasselbalch H
PLoS One; 2012; 7(3):e33100. PubMed ID: 22403733
[TBL] [Abstract][Full Text] [Related]
2. Quantitative threefold allele-specific PCR (QuanTAS-PCR) for highly sensitive JAK2 V617F mutant allele detection.
Zapparoli GV; Jorissen RN; Hewitt CA; McBean M; Westerman DA; Dobrovic A
BMC Cancer; 2013 Apr; 13():206. PubMed ID: 23617802
[TBL] [Abstract][Full Text] [Related]
3. [JAK2 exon 12 mutations in patients with Philadelphia (Ph) chromosome-negative myeloproliferative neoplasms].
Wang JY; Ai XF; Xu JQ; Li QH; Xu ZF; Qin TJ; Zang Y; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2012 Sep; 33(9):705-9. PubMed ID: 23336221
[TBL] [Abstract][Full Text] [Related]
4. Analysis of JAK2V617F mutation in Jordanian patients with myeloproliferative neoplasms.
Jaradat SA; Khasawneh R; Kamal N; Matalka I; Al-Bishtawi M; Al-Sweedan S; Ayesh MH
Hematol Oncol Stem Cell Ther; 2015 Dec; 8(4):160-6. PubMed ID: 26256826
[TBL] [Abstract][Full Text] [Related]
5. Next-generation sequencing for JAK2 mutation testing: advantages and pitfalls.
Maslah N; Verger E; Schlageter MH; Miclea JM; Kiladjian JJ; Giraudier S; Chomienne C; Cassinat B
Ann Hematol; 2019 Jan; 98(1):111-118. PubMed ID: 30259120
[TBL] [Abstract][Full Text] [Related]
6. Rapid identification of JAK2 exon 12 mutations using high resolution melting analysis.
Jones AV; Cross NC; White HE; Green AR; Scott LM
Haematologica; 2008 Oct; 93(10):1560-4. PubMed ID: 18698085
[TBL] [Abstract][Full Text] [Related]
7. Accurate quantitation of JAK2 V617F allele burden by array-based digital PCR.
Kinz E; Leiherer A; Lang AH; Drexel H; Muendlein A
Int J Lab Hematol; 2015 Apr; 37(2):217-24. PubMed ID: 24963593
[TBL] [Abstract][Full Text] [Related]
8. The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms.
Borowczyk M; Wojtaszewska M; Lewandowski K; Gil L; Lewandowska M; Lehmann-Kopydłowska A; Kroll-Balcerzak R; Balcerzak A; Iwoła M; Michalak M; Komarnicki M
Thromb Res; 2015 Feb; 135(2):272-80. PubMed ID: 25559461
[TBL] [Abstract][Full Text] [Related]
9. Increased frequency of co-existing JAK2 exon-12 or MPL exon-10 mutations in patients with low JAK2(V617F) allelic burden.
Nussenzveig RH; Pham HT; Perkins SL; Prchal JT; Agarwal AM; Salama ME
Leuk Lymphoma; 2016; 57(6):1429-35. PubMed ID: 26419289
[TBL] [Abstract][Full Text] [Related]
10. The clinical and prognostic relevance of driver mutations in 203 Taiwanese patients with primary myelofibrosis.
Kuo MC; Lin TH; Sun CF; Lin TL; Wu JH; Wang PN; Huang YJ; Chang H; Huang TY; Shih LY
J Clin Pathol; 2018 Jun; 71(6):514-521. PubMed ID: 29203554
[TBL] [Abstract][Full Text] [Related]
11. [Usefulness of real-time semi-quantitative PCR, JAK2 MutaScreen kit for JAK2 V617F screening].
Chae H; Lee JH; Lim J; Jung SW; Kim M; Kim Y; Han K; Cho BS; Cho SG; Lee JW; Min WS
Korean J Lab Med; 2009 Jun; 29(3):243-8. PubMed ID: 19571623
[TBL] [Abstract][Full Text] [Related]
12. Detection of low allele burden of JAK2 exon 12 mutations using TA-cloning in patients with erythrocytosis.
Ohyashiki JH; Hisatomi H; Shimizu S; Sugaya M; Ohyashiki K
Jpn J Clin Oncol; 2009 Aug; 39(8):509-13. PubMed ID: 19491085
[TBL] [Abstract][Full Text] [Related]
13. JAK2V617F allele burden in patients with myeloproliferative neoplasms.
Alshemmari SH; Rajaan R; Ameen R; Al-Drees MA; Almosailleakh MR
Ann Hematol; 2014 May; 93(5):791-6. PubMed ID: 24362471
[TBL] [Abstract][Full Text] [Related]
14. Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms.
Gángó A; Mózes R; Boha Z; Kajtár B; Timár B; Király PA; Kiss R; Fésüs V; Nagy N; Demeter J; Körösmezey G; Borbényi Z; Marton I; Szőke A; Masszi T; Farkas P; Várkonyi J; Plander M; Pósfai É; Egyed M; Pál K; Radványi G; Hamed A; Csomor J; Matolcsy A; Alpár D; Bödör C
Leuk Res; 2018 Feb; 65():42-48. PubMed ID: 29306106
[TBL] [Abstract][Full Text] [Related]
15. Polycythaemia Vera among Sudanese Patients with Special Emphasis on JAK2 Mutations.
Ibrahim IK; Hassan R; Ali EW; Omer A
Asian Pac J Cancer Prev; 2019 Jan; 20(1):41-44. PubMed ID: 30677867
[TBL] [Abstract][Full Text] [Related]
16. Study on the Clinical Significance of JAK2V617F Allele Burden in Philadelphia Chromosome-Negative Myeloproliferative Neoplasm.
Chen P; Ouyang J; Liang J; Yu X; Huang B
Clin Lab; 2016 Aug; 62(8):1477-1481. PubMed ID: 28164603
[TBL] [Abstract][Full Text] [Related]
17. Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms.
Frawley T; O'Brien CP; Conneally E; Vandenberghe E; Percy M; Langabeer SE; Haslam K
Genet Test Mol Biomarkers; 2018 Feb; 22(2):98-103. PubMed ID: 29323541
[TBL] [Abstract][Full Text] [Related]
18. Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms.
Trung NT; Quyen DT; Hoan NX; Giang DP; Trang TTH; Velavan TP; Bang MH; Song LH
BMC Med Genet; 2019 Jun; 20(1):115. PubMed ID: 31248375
[TBL] [Abstract][Full Text] [Related]
19. Rapid and sensitive detection of CALR exon 9 mutations using high-resolution melting analysis.
Lim KH; Lin HC; Chen CG; Wang WT; Chang YC; Chiang YH; Lin CS; Su NW; Su YW; Lin J; Chang YF; Chang MC; Hsieh RK; Kuo YY; Chou WC
Clin Chim Acta; 2015 Feb; 440():133-9. PubMed ID: 25447704
[TBL] [Abstract][Full Text] [Related]
20. Influence of JAK2 46/1 haplotype in the natural evolution of JAK2V617F allele burden in patients with myeloproliferative neoplasms.
Alvarez-Larrán A; Angona A; Martínez-Avilés L; Bellosillo B; Besses C
Leuk Res; 2012 Mar; 36(3):324-6. PubMed ID: 22001278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]